A certain group of monocytes was especially likely to become infected: those carrying a receptor called CD16. These “non-classic” monocytes make up only about 10 percent of all monocytes ...

A new area of cancer immunotherapy is enhancing therapeutic mAb-mediated CD16 activation of NK cells. CAR-NK cells containing multi-specific molecules made up of relatively stable CD16 and other ...

Specifically, CD62L-CD86 + myeloid dendritic cells and CD86 + myeloid dendritic cells demonstrated protective effects, whereas CD14 + CD16 + monocytes were identified as risk factors. Furthermore, the ...